ArticleFrontiers in human neuroscience2025
The role of blood-brain barrier dysfunction in cognitive impairments in bipolar disorder-a narrative review.
Article in Frontiers in human neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Role of the Blood-Brain Barrier in the Pathophysiology of Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A Comparative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Multimodal EEG-fNIRS classification as a clinical tool for bipolar disorder diagnosis.Translational psychiatry · 2026Article
- Immune dysregulation and neuroinflammation in bipolar disorder: Pathophysiological insights and therapeutic perspectives.Brain, behavior, & immunity - health · 2026Review
- The Breakdown of Neurovascular Barriers: Molecular Mechanisms of Tight Junction Dysfunction.Molecular neurobiology · 2025Review
- Across Barriers: Blood-Brain and Gut Barrier Signaling in Psychiatric Disorders.Journal of neurochemistry · 2025Review
- Restoring brain barriers: an innovative approach for treating neurological disorders.Fluids and barriers of the CNS · 2025Review
- Melatonin as a Neuroprotective Adjunct in Bipolar Patients Undergoing Electroconvulsive Therapy: A Double-blind Randomized Controlled Trial.Basic and clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bipolar disorder (BD) is a chronic and debilitating mental illness affecting approximately 40 million people worldwide. Cognitive impairment is a core feature of BD, impacting daily functioning and persisting even during mood stability. Cognitive deficits are among the most reliable indicators of long-term functional outcomes in BD. Despite their significance, there are currently no widely available treatments targeting cognitive impairment in BD, largely due to our limited understanding of the underlying pathophysiology. A healthy blood-brain barrier (BBB) is essential for brain homeostasis, serving as a protective filter that restricts peripheral toxins, pathogens, and ions from entering the brain and disrupting neuronal function. Increased BBB permeability can allow harmful substances to infiltrate the brain, potentially leading to neuroinflammation, disrupted signaling, and damage to brain tissue, all of which may contribute to cognitive impairments in BD. Thus, BBB dysfunction could represent an upstream driver of cognitive impairment in BD, offering a potential target for disease-modifying interventions. This narrative review examined the evidence for the link between BBB permeability and cognitive deficits in BD. Our search yielded limited studies with mixed findings, highlighting the significant need for further research to explore this critical area and its potential for developing disease-modifying treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.